{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:39Z","timestamp":1791312099995,"version":"4.3.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T00:00:00Z","timestamp":1525478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T00:00:00Z","timestamp":1525478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11908-018-0617-x","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T08:37:44Z","timestamp":1525509464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms"],"prefix":"10.1007","volume":"20","author":[{"given":"Ann Marie","family":"Porreca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaede V.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,5]]},"reference":[{"issue":"1","key":"617_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1469-0691.2011.03478.x","volume":"18","author":"D Ben-David","year":"2017","unstructured":"\u2022\u2022 Ben-David D, Kordevani R, Keller N, Tai I, Marzel O, Gal-Mor Y, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2017;18(1):54\u201360. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03478.x. This article illustrated the impact that carbapenem-resistant K. pneumoniae had on mortality in patients with bloodstream infections.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"617_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1086\/592412","volume":"29","author":"G Patel","year":"2008","unstructured":"Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099\u2013106. https:\/\/doi.org\/10.1086\/592412.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"617_CR3","unstructured":"\u2022\u2022 World Health Organization. Global Antimicrobial Resistance Surveillance System. Manual for Early Implementation. WHO. 2015:1\u201344. http:\/\/www.who.int\/drugresistance\/en\/%5Cnwww.who.int\/about\/licensing\/copyright_form\/en\/index.%5Cnhttp:\/\/apps.who.int\/iris\/bitstream\/10665\/188783\/1\/9789241549400_eng.pdf?ua=1. This reference is important because it emphasized the current emergence of Klebsiella pneumoniae carbapenemases globally."},{"key":"617_CR4","doi-asserted-by":"publisher","unstructured":"\u2022 Centers for Disease Control and Prevention. Tracking CRE. CDC. 2017;2010:2009\u201310. https:\/\/doi.org\/10.1086\/668770. This report revealed that all states, with exception of Maine and Idaho, reported cases of Klebsiella pneumoniae carbapenemase-producing organisms","DOI":"10.1086\/668770"},{"issue":"10","key":"617_CR5","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1128\/AAC.01019-15","volume":"59","author":"JDD Pitout","year":"2015","unstructured":"\u2022 Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59(10):5873\u201384. https:\/\/doi.org\/10.1128\/AAC.01019-15. This paperrevealed how ST258 predominates in the United States and around the world, suggesting a possible selective or fitness advantage over other clones","journal-title":"Antimicrob Agents Chemother"},{"key":"617_CR6","doi-asserted-by":"publisher","unstructured":"Yigit H, Queenan AM, Rasheed JK, Biddle JW, Domench-Sanchez A, Alberti S, et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob Agents Chemother. 2003;47(12):3881\u20139. https:\/\/doi.org\/10.1128\/AAC.47.12.3881.","DOI":"10.1128\/AAC.47.12.3881"},{"issue":"1","key":"617_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-06256-2","volume":"7","author":"N Stoesser","year":"2017","unstructured":"Stoesser N, Sheppard AE, Peirano G, Anson LW, Pankhurst L, Sebra R, et al. Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli. Sci Rep. 2017;7(1):1\u201311. https:\/\/doi.org\/10.1038\/s41598-017-06256-2.","journal-title":"Sci Rep"},{"issue":"7","key":"617_CR8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3201\/eid1407.070826","volume":"14","author":"FG Pasteran","year":"2008","unstructured":"Pasteran FG, Otaegui L, Guerriero L, Radice G, Maggiora R, Rapoport M, et al. Klebsiella pneumoniae carbapenemase-2, Buenos Aires. Argentina Emerg Infect Diseas. 2008;14(7):1178\u201380. https:\/\/doi.org\/10.3201\/eid1407.070826.","journal-title":"Argentina Emerg Infect Diseas"},{"issue":"4","key":"617_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.diagmicrobio.2006.07.004","volume":"56","author":"LM Deshpande","year":"2006","unstructured":"Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC program (1999-2005). Diagn Microbiol Infect Dis. 2006;56(4):367\u201372. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2006.07.004.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"617_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1128\/AAC.00641-09","volume":"53","author":"A Endimiani","year":"2009","unstructured":"Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with\u00a0beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother. 2009;53(8):3599\u2013601. https:\/\/doi.org\/10.1128\/AAC.00641-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"617_CR11","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","volume":"45","author":"H Yigit","year":"2001","unstructured":"Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing \u03b2-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151\u201361. https:\/\/doi.org\/10.1128\/AAC.45.4.1151.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"617_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1128\/AAC.47.4.1297-1300.2003","volume":"47","author":"V Miriagou","year":"2003","unstructured":"Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother. 2003;47(4):1297\u2013300. https:\/\/doi.org\/10.1128\/AAC.47.4.1297-1300.2003.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"617_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/jac\/dkg124","volume":"51","author":"ES Moland","year":"2003","unstructured":"Moland ES, Hanson ND, Herrera VL, Black JA, Lockhart TJ, Hossain A, et al. Plasmid-mediated, carbapenem-hydrolysing \u03b2-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother. 2003;51(3):711\u20134. https:\/\/doi.org\/10.1093\/jac\/dkg124.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"617_CR14","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.48.12.4793-4799.2004","volume":"48","author":"N Woodford","year":"2004","unstructured":"Woodford N, Tierno PM, Young K, Tysall L, Palepou MF, Ward E, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem hydrolyzing class A of beta-lactamase, KPC-3, in a New York medical center. J Antimicrob Agents Chemother. 2004;48(12):4793\u20139. https:\/\/doi.org\/10.1128\/AAC.48.12.4793.","journal-title":"J Antimicrob Agents Chemother"},{"issue":"10","key":"617_CR15","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1093\/jac\/dkw242","volume":"71","author":"M Abdallah","year":"2016","unstructured":"\u2022 Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Ghithan M, et al. Rise and fall of KPC-producing Klebsiella pneumoniae in New York City. J Antimicrob Chemother. 2016;71(10):2945\u20138. https:\/\/doi.org\/10.1093\/jac\/dkw242. This reference depicted that some hospitals in New York City were reporting that nearly half of their K. pneumoniae isolates carried bla\n                              \n                      KPC\n                     genes","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"617_CR16","doi-asserted-by":"publisher","first-page":"ofw222","DOI":"10.1093\/ofid\/ofw222","volume":"3","author":"SO Park","year":"2016","unstructured":"\u2022 Park SO, Liu J, Furuya EY, Larson EL. Carbapenem-resistant Klebsiella pneumoniae infection in three New York City hospitals trended downwards from 2006 to 2014. Open Forum Infect Dis. 2016;3(4):ofw222. https:\/\/doi.org\/10.1093\/ofid\/ofw222. This paper reported that New York City saw a significant decline in prevalence of Klebsiella pneumoniae carbapenemases and suggested that reduction of indwelling device utilization improved techniques for sterilization of endoscopes, and application of infection prevention strategies may have contributed to this decline","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"617_CR17","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1128\/AAC.49.10.4423-4424.2005","volume":"49","author":"T Naas","year":"2005","unstructured":"Naas T, Nordmann P. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. J Antimicrob Agents Chemother. 2005;49(10):4423\u20134. https:\/\/doi.org\/10.1128\/AAC.49.10.4423.","journal-title":"J Antimicrob Agents Chemother"},{"issue":"9","key":"617_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","volume":"13","author":"LS Munoz-Price","year":"2013","unstructured":"Munoz-Price LS, Poirel L, Bonomo R, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785\u201396. https:\/\/doi.org\/10.1016\/S1473-3099(13)70190-7.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"617_CR19","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ajic.2016.03.022","volume":"44","author":"AC Campos","year":"2016","unstructured":"\u2022\u2022 Campos AC, Albiero J, Ecker AB, Kuroda CM, Meirelles L, Polato A, et al. Outbreak of Klebsiella pneumoniae carbapenemase\u2013producing K pneumoniae: a systematic review. Am J Infect Control. 2016;44(11):1374\u201380. https:\/\/doi.org\/10.1016\/j.ajic.2016.03.022. This article reviewed outbreaks of Klebsiella pneumoniae carbapenemases and factors associated with them","journal-title":"Am J Infect Control"},{"issue":"6","key":"617_CR20","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1017\/ice.2017.62","volume":"38","author":"K Okamoto","year":"2017","unstructured":"\u2022 Okamoto K, Lin MY, Haverkate M, Lolans K, Moore NM, Weiner S, et al. Modifiable risk factors for the spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae among long-term acute-care hospital patients. Infect Control Hosp Epidemiol. 2017;38(6):670\u20137. https:\/\/doi.org\/10.1017\/ice.2017.62. This article reviewed the risk factors for acquisition of Klebsiella pneumoniae carbapenemase-producing organisms","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"617_CR21","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1128\/AAC.02636-14","volume":"58","author":"D Van Duin","year":"2014","unstructured":"Van Duin D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother. 2014;58(7):4035\u201341. https:\/\/doi.org\/10.1128\/AAC.02636-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"617_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1086\/668435","volume":"33","author":"K Prabaker","year":"2012","unstructured":"Prabaker K, Lin MY, McNally M, Cherabuddi K, Ahmed S, Norris A, et al. Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase\u2013producing Enterobacteriaceae: a multihospital tudy. Infect Control Hosp Epidemiol. 2012;33(12):1193\u20139. https:\/\/doi.org\/10.1086\/668435.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"617_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajic.2013.12.001","volume":"42","author":"C L\u00fcbbert","year":"2014","unstructured":"L\u00fcbbert C, Lippmann N, Busch T, Kaisers UX, Ducomble T, Eckmanns T, et al. Long-term carriage of Klebsiella pneumoniae carbapenemase-2-producing K pneumoniae after a large single-center outbreak in Germany. Am J Infect Control. 2014;42(4):376\u201380. https:\/\/doi.org\/10.1016\/j.ajic.2013.12.001.","journal-title":"Am J Infect Control"},{"issue":"1","key":"617_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1128\/AAC.04306-14","volume":"59","author":"E Leitner","year":"2015","unstructured":"\u2022 Leitner E, Zarfel G, Luxner J, Herzog K, Pekard-Amenitsch S, Martin H, et al. Contaminated handwashing sinks as the source of a clonal outbreak of KPC-2-producing Klebsiella oxytoca on a hematology ward. Antimicrob Agents Chemother. 2015;59(1):714\u20136. https:\/\/doi.org\/10.1128\/AAC.04306-14. This paper described a prolonged outbreak involving K. oxytoca with bla\n                              \n                      KPC\n                     in an Austrian hematology ward for which contaminated mesh sink drains may have been the source. Renewed enforcement of contact precautions, hand hygiene, and cleaning of the environment eventually controlled the outbreak","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"617_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1086\/651097","volume":"31","author":"LS Munoz-Price","year":"2010","unstructured":"Munoz-Price LS, Hayden MK, Lolans K, Won S, Calvert K, Lin M, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase\u2014producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol. 2010;31(4):341\u20137. https:\/\/doi.org\/10.1086\/651097.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"617_CR26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/cid\/ciu1173","volume":"60","author":"MK Hayden","year":"2015","unstructured":"\u2022 Hayden MK, Lin MY, Lolans K, Weiner S, Blom D, Moore NM, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis. 2015;60(8):1154\u201361. https:\/\/doi.org\/10.1093\/cid\/ciu1173. This paper investigated interventions to reduce patient to patient transmission of Klebsiella pneumoniae carbapenemases","journal-title":"Clin Infect Dis"},{"issue":"6","key":"617_CR27","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1128\/JCM.00820-15","volume":"53","author":"NF Crum-Cianflone","year":"2015","unstructured":"\u2022\u2022 Crum-Cianflone NF, Sullivan E, Ballon-Landa G. Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol. 2015;53(6):1986\u20139. https:\/\/doi.org\/10.1128\/JCM.00820-15. This paper discussed a novel approach of displacing multi-drug resistant organisms by using fecal microbiota transplantation","journal-title":"J Clin Microbiol"},{"issue":"10","key":"617_CR28","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1128\/AAC.03564-14","volume":"58","author":"JC Gallagher","year":"2014","unstructured":"Gallagher JC, Kuriakose S, Haynes K, Axelrod P. Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2014;58(10):5732\u20135. https:\/\/doi.org\/10.1128\/AAC.03564-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"617_CR29","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3109\/00365548.2014.923106","volume":"46","author":"M Papadimitriou-Olivgeris","year":"2014","unstructured":"Papadimitriou-Olivgeris M, Marangos M, Christofidou M, Fligou F, Bartzavali C, Panteli ES, et al. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. Scand J Infect Dis. 2014;46(9):642\u20138. https:\/\/doi.org\/10.3109\/00365548.2014.923106.","journal-title":"Scand J Infect Dis"},{"issue":"17","key":"617_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/MD.0000000000000111","volume":"93","author":"N Girometti","year":"2014","unstructured":"Girometti N, Lewis RE, Giannella M, Ambretti S, Bartoletti M, Tedeschi S, et al. Klebsiella pneumoniae bloodstream infection. Medicine. 2014;93(17):298\u2013309. https:\/\/doi.org\/10.1097\/MD.0000000000000111.","journal-title":"Medicine"},{"issue":"7","key":"617_CR31","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","volume":"17","author":"B Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B, Salamanca E, de Cueto M, Hsueh P, Viale P, Pano-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726\u201334. https:\/\/doi.org\/10.1016\/S1473-3099(17)30228-1.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"617_CR32","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1128\/AAC.00533-15","volume":"59","author":"A Adler","year":"2015","unstructured":"Adler A, Ben-Dalak M, Chmelnitsky I, Carmeli Y. Effect of resistance mechanisms on the inoculum effect of carbapenem in Klebsiella pneumoniae isolates with borderline carbapenem resistance. Antimicrob Agents Chemother. 2015;59(8):5014\u20137. https:\/\/doi.org\/10.1128\/AAC.00533-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"617_CR33","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/jac\/dkv086","volume":"70","author":"M Tumbarello","year":"2015","unstructured":"Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133\u201343. https:\/\/doi.org\/10.1093\/jac\/dkv086.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"617_CR34","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1128\/AAC.01420-10","volume":"55","author":"CC Bulik","year":"2011","unstructured":"Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(6):3002\u20134. https:\/\/doi.org\/10.1128\/AAC.01420-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"617_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1128\/AAC.01569-15","volume":"60","author":"JB Cprek","year":"2015","unstructured":"\u2022 Cprek JB, Gallagher JC. Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;60(1):669\u201373. https:\/\/doi.org\/10.1128\/AAC.01569-15. This article described outcomes of patients that received double-carbapenem regimens for Klebsiella pneumoniae carbapenemase-producing infections","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"617_CR36","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/jac\/dku027","volume":"69","author":"A Oliva","year":"2014","unstructured":"Oliva A, D\u2019Abramo A, D\u2019Agostino C, Ianetta M, Mascellino MT, Gallinelli C, et al. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. J Antimicrob Chemother. 2014;69(6):1718\u201320. https:\/\/doi.org\/10.1093\/jac\/dku027.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"617_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13054-017-1769-z","volume":"21","author":"G De Pascale","year":"2017","unstructured":"\u2022\u2022 De Pascale G, Martucci G, Montini L, Panarello G, Cutuli SL, Di Carlo D, et al. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case\u2013control study. Crit Care. 2017;21(1):173. https:\/\/doi.org\/10.1186\/s13054-017-1769-z. This study evaluated the effiacy of double-carbapenem coverage reigmens and outcomes compared to standard regimens","journal-title":"Crit Care"},{"issue":"5","key":"617_CR38","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1128\/AAC.05055-14","volume":"59","author":"A Jayol","year":"2015","unstructured":"\u2022\u2022 Jayol A, Nordmann P, Brink A, Poirel L. Heteroresistance to colistin in Klebsiella pneumoniae associated with alterations in the PhoPQ regulatory system. Antimicrob Agents Chemother. 2015;59(5):2780\u20134. https:\/\/doi.org\/10.1128\/AAC.05055-14. This paper reviewed mechanisms of resistance of Klebsiella pneumoniae carbapenemases to carbapenems","journal-title":"Antimicrob Agents Chemother"},{"key":"617_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drup.2010.05.002","volume":"13","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Updat. 2010;13:132\u20138. https:\/\/doi.org\/10.1016\/j.drup.2010.05.002.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"617_CR40","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1128\/AAC.01870-15","volume":"60","author":"PA Bradford","year":"2016","unstructured":"Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF. Correlation of\u00a0beta-lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program. Antimicrob Agents Chemother. 2016;60(3):1385\u201392. https:\/\/doi.org\/10.1128\/AAC.01870-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"617_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2012.07.010","volume":"74","author":"PJ Bergen","year":"2012","unstructured":"Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Le HJ, Nation RL, et al. Pharmacokinetics and pharmacodynamics of \u201cold\u201d polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74(3):213\u201323. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.07.010.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"617_CR42","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 et al. Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard J, Bulitta JB, Optimizing polymyxin combinations against resistant Gram-negative bacteria. Infect Dis Ther. 2015;4(4):391\u2013415. https:\/\/doi.org\/10.1007\/s40121-015-0093-7. This article discussed how to optimize polymyxin administration in combination with other agents for infections due to resistant Gram-negatives","DOI":"10.1007\/s40121-015-0093-7"},{"issue":"2","key":"617_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4021\/jocmr1220w","volume":"5","author":"GC Lee","year":"2013","unstructured":"Lee GC, Burgess DS. Polymyxins and doripenem combination against KPC-producing Klebsiella pneumoniae. J Clin Med Res. 2013;5(2):97\u2013100. https:\/\/doi.org\/10.4021\/jocmr1220w.","journal-title":"J Clin Med Res"},{"issue":"7","key":"617_CR44","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.01733-10","volume":"55","author":"SM Garonzik","year":"2011","unstructured":"Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284\u201394. https:\/\/doi.org\/10.1128\/AAC.01733-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"617_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524\u201331. https:\/\/doi.org\/10.1093\/cid\/cit334.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"617_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/cid\/ciw839","volume":"64","author":"RL Nation","year":"2017","unstructured":"\u2022\u2022 Nation RL, Garonzik SM, Thamlikitkul V, Giamarello-Bourboulis EJ, Forrest A, Paterson DL, et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis. 2017;64(5):565\u201371. https:\/\/doi.org\/10.1093\/cid\/ciw839. This paper reviewed the relationship between colistin dosing and renal function and outcomes","journal-title":"Clin Infect Dis"},{"issue":"4","key":"617_CR47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/21505594.2016.1221021","volume":"8","author":"EA Neuner","year":"2017","unstructured":"\u2022\u2022 Neuner EA, Gallagher JC. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8(4):440\u201352. https:\/\/doi.org\/10.1080\/21505594.2016.1221021. This article stressed the importance of the uncertainty of polymyxins to achieve adqueate lung concentrations","journal-title":"Virulence"},{"key":"617_CR48","unstructured":"Polymyxin B [package insert]. Breckenridge Pharmaceutical Inc., Boca Raton, FL; 2016."},{"issue":"4","key":"617_CR49","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1128\/AAC.02634-15","volume":"60","author":"MH Rigatto","year":"2016","unstructured":"\u2022\u2022 Rigatto MH, Oliveira MS, Perdig\u00e3o-Neto LV, Levin AS, Carrilho CM, Tanita MT, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443\u20139. https:\/\/doi.org\/10.1128\/AAC.02634-15. This article reviewed the increased risk of renal failure associated with colistin compared to polymyxin","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"617_CR50","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1128\/AAC.02476-13","volume":"58","author":"K Phe","year":"2014","unstructured":"Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin b therapy. Antimicrob Agents Chemother. 2014;58(5):2740\u20136. https:\/\/doi.org\/10.1128\/AAC.02476-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"617_CR51","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/cid\/cit453","volume":"57","author":"DS Akajagbor","year":"2013","unstructured":"Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin b in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013;57(9):1300\u20133. https:\/\/doi.org\/10.1093\/cid\/cit453.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"617_CR52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jinf.2013.04.017","volume":"67","author":"FF Tuon","year":"2013","unstructured":"Tuon FF, Rocha JL, Formighieri MS, Sfair S, Bertoldi MB, Palmeiro JK, et al. Fosfomycin susceptibility of isolates with blaKPC-2 from Brazil. J Inf Secur. 2013;67(3):247\u20139. https:\/\/doi.org\/10.1016\/j.jinf.2013.04.017.","journal-title":"J Inf Secur"},{"issue":"4","key":"617_CR53","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/jac\/dkl315","volume":"58","author":"MJ Ellington","year":"2006","unstructured":"Ellington MJ, Livermore DM, Pitt TL, Hall LMC, Woodford N. Mutators among CTX-M\u00a0beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother. 2006;58(4):848\u201352. https:\/\/doi.org\/10.1093\/jac\/dkl315.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"617_CR54","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijantimicag.2017.03.011","volume":"50","author":"W Yu","year":"2017","unstructured":"Yu W, Shen P, Bao Z, Zhou K, Zheng B, Ji J, et al. In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2017;50(2):237\u201341. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.011.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"617_CR55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","volume":"15","author":"AP Zavascki","year":"2017","unstructured":"\u2022 Zavascki AP, Klee BO, Bulitta JB. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther. 2017;15(6):519\u201326. https:\/\/doi.org\/10.1080\/14787210.2017.1316193. This article discussed the limitations of aminoglycoside susceptibility and minimum inhibitory concentration datas in serving as valid predictors of clinical success","journal-title":"Expert Rev Anti Infect Ther"},{"key":"617_CR56","doi-asserted-by":"publisher","unstructured":"Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, et al. ACHN-490, a neoglycoside with potent in vitro activity against multi-drug resistant Klebsiella pnemoniae isolates. Antimicro Agents Chemo Ther. 2009;53:4504\u20137. https:\/\/doi.org\/10.1128\/AAC.00641-09.","DOI":"10.1128\/AAC.00641-09"},{"issue":"10","key":"617_CR57","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1128\/AAC.00784-09","volume":"53","author":"B Kitchel","year":"2009","unstructured":"Kitchel B, Sundin DR, Patel JB. Regional dissemination of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2009;53(10):4511\u20133. https:\/\/doi.org\/10.1128\/AAC.00784-09.","journal-title":"Antimicrob Agents Chemother"},{"key":"617_CR58","unstructured":"United States Committee on Antimicrobial Susceptibility Testing ( USCAST ). MIC Breakpoint Tables Comparing the Interpretive Criteria of CLSI, EUCAST, USA-FDA and USCAST. 2015:1\u20138."},{"key":"617_CR59","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/1469-0691.12697","volume":"20","author":"LS Tzouvelekis","year":"2014","unstructured":"Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobactericeae. Clin Microbiol Infect Dis. 2014;20:862\u201372. https:\/\/doi.org\/10.1111\/1469-0691.12697.","journal-title":"Clin Microbiol Infect Dis"},{"issue":"6","key":"617_CR60","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.clinthera.2012.05.002","volume":"34","author":"BT Alexander","year":"2012","unstructured":"Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne WM, Ritchie DJ. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther. 2012;34(6):1314\u201323. https:\/\/doi.org\/10.1016\/j.clinthera.2012.05.002.","journal-title":"Clin Ther"},{"issue":"12","key":"617_CR61","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1128\/AAC.00387-11","volume":"55","author":"MJ Satlin","year":"2011","unstructured":"Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya E, Wilson SJ, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55(12):5893\u20139. https:\/\/doi.org\/10.1128\/AAC.00387-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"617_CR62","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/1469-0691.12697","volume":"20","author":"LS Tzouvelekis","year":"2014","unstructured":"Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20(9):862\u201372. https:\/\/doi.org\/10.1111\/1469-0691.12697.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"617_CR63","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1592\/phco.30.6.562","volume":"30","author":"J Le","year":"2010","unstructured":"Le J, Ashley ED, Neuhauser MM, Brown J, Gentry C, Klepser ME, et al. Consensus aummary of aerosolized antimicrobial agents\u00a0: application of guideline criteria insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2010;30(6):562\u201384. https:\/\/doi.org\/10.1592\/phco.30.6.562.","journal-title":"Pharmacotherapy"},{"key":"617_CR64","doi-asserted-by":"publisher","unstructured":"Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations\u00a0: results from the SENTRY surveillance program ( 2010\u20132013 ). Diagn Microbiol Infect Dis 2015:83(2):183\u2013186. doi:https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.06.011.","DOI":"10.1016\/j.diagmicrobio.2015.06.011"},{"issue":"2","key":"617_CR65","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","volume":"75","author":"D Van Duin","year":"2013","unstructured":"Van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115\u201320. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.11.009.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"617_CR66","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","volume":"68","author":"AT Freire","year":"2010","unstructured":"Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et al. Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140\u201351. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.05.012.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"617_CR67","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/0091270003257225","volume":"43","author":"JL Kuti","year":"2003","unstructured":"Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003;43(10):1116\u201323. https:\/\/doi.org\/10.1177\/0091270003257225.","journal-title":"J Clin Pharmacol"},{"key":"617_CR68","doi-asserted-by":"publisher","unstructured":"Di Carlo P, Gulotta G, Casuccio A, Pantuso G, Raineri M, Farulla CA, et al. KPC - 3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting\u00a0: analysis of a case series of 30 patients. BMC Anesthesio. 2013:1\u20138. https:\/\/doi.org\/10.1186\/1471-2253-13-13.","DOI":"10.1186\/1471-2253-13-13"},{"key":"617_CR69","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/cid\/cis969","volume":"56","author":"F Sbrana","year":"2013","unstructured":"Sbrana F, Malacarne P, Viaggi B, Costanzo S, Lenonetti P, Leonildi A, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae Carbapenemase \u2013 Producing K. Pneumoniae in intensive care unit. Clin Infect Dis. 2013;56:697\u2013700. https:\/\/doi.org\/10.1093\/cid\/cis969.","journal-title":"Clin Infect Dis"},{"key":"617_CR70","unstructured":"FDA. A drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. 2013. http:\/\/www.fda.gov\/%5CnDrugs\/DrugSafety\/ucm369580.htm."},{"issue":"29","key":"617_CR71","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, Jahi\u0107 H, Ross PL, Gu RF, Hu J, Kern G, et al. Avibactam is a covalent, reversible, non\u2013\u03b2-lactam \u03b2-lactamase inhibitor. Proc Natl Acad Sci. 2012;109(29):11663\u20138. https:\/\/doi.org\/10.1073\/pnas.1205073109.","journal-title":"Proc Natl Acad Sci"},{"key":"617_CR72","doi-asserted-by":"publisher","unstructured":"Castanheira M, Williams G, Jones RN, Sader HS. Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying \u03b2-lactamases prevalent in the United States. Microb Drug Resist 2014: 0(0):1\u20135. Doi:https:\/\/doi.org\/10.1089\/mdr.2013.0181.","DOI":"10.1089\/mdr.2013.0181"},{"issue":"6","key":"617_CR73","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"\u2022 Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661\u201373. https:\/\/doi.org\/10.1016\/S1473-3099(16)30004-4. This study illustrated the efficacy of ceftazidime-avibactam in patients infected with resistant organisms","journal-title":"Lancet Infect Dis"},{"key":"617_CR74","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1128\/AAC.01198-10","volume":"55","author":"A Endimiani","year":"2011","unstructured":"Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:82\u20135. https:\/\/doi.org\/10.1128\/AAC.01198-10.","journal-title":"Antimicrob Agents Chemother"},{"key":"617_CR75","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1128\/AAC.03267-14","volume":"58","author":"SH Macvane","year":"2014","unstructured":"Macvane SH, Crandon JL, Nichols WW, Nicolau DP. In vivo efficacy of humanized exposures of ceftazidime-avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2014;58:6913\u20139. https:\/\/doi.org\/10.1128\/AAC.01198-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"31","key":"617_CR76","doi-asserted-by":"publisher","first-page":"e7664","DOI":"10.1097\/MD.0000000000007664","volume":"96","author":"A Gugliandolo","year":"2017","unstructured":"Gugliandolo A, Caio C, Mezzatesta ML, Rifici C, Bramanti P, Stefani S, et al. Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury. Medicine (Baltimore). 2017;96(31):e7664. https:\/\/doi.org\/10.1097\/MD.0000000000007664.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"617_CR77","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/cid\/ciw491","volume":"63","author":"G Wu","year":"2016","unstructured":"\u2022\u2022 Wu G, Abraham T, Lee S. Ceftazidime-Avibactam for treatment of carbapenem-eesistant Enterobacteriaceae bacteremia. Clin Infect Dis. 2016;63(8):1147\u20138. https:\/\/doi.org\/10.1093\/cid\/ciw491. This article evaluated the efficacy of the new-beta lactam inhibitor combination for the treatment of carbapenem resistant Enterobacteriacea bacteremia","journal-title":"Clin Infect Dis"},{"issue":"2","key":"617_CR78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijantimicag.2016.06.002","volume":"48","author":"DM Jacobs","year":"2016","unstructured":"Jacobs DM, DiTursi S, Ruh C, Sharma R, Claus J, Banjade R, et al. Combination treatment with extended-infusion ceftazidime\/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient. Int J Antimicrob Agents. 2016;48(2):225\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.06.002.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"617_CR79","doi-asserted-by":"publisher","first-page":"e00449","DOI":"10.1128\/AAC.00449-17","volume":"61","author":"M King","year":"2017","unstructured":"King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;61(7):e00449\u201317. https:\/\/doi.org\/10.1128\/AAC.00449-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"617_CR80","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Shields RK, Nguyen MH, Chen L, Press EC, Potoski BA, Marini RA, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8) https:\/\/doi.org\/10.1128\/AAC.00883-17. This article showed superiority of ceftazidime-avibactam over available options for the treatment of carbapenem-reisistant bacteremia","DOI":"10.1128\/AAC.00883-17"},{"key":"617_CR81","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Van Duin D, Lok JJ, Earley M, Cober E, Richter S, Perez F, et al. Colistin vs. ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2017;cix 783 https:\/\/doi.org\/10.1093\/cid\/cix783\/4103289. This study showed that ceftazidime-avibactam is better than colistin for treatment of carbapenem-resistant Enterobacteriaceae","DOI":"10.1093\/cid\/cix783\/4103289"},{"key":"617_CR82","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother. 2015;59(10):6605\u20137. Doi:https:\/\/doi.org\/10.1128\/AAC.01165-15. This was the the first report of ceftazidime-avibactam resistance in a KPC isolate, indicating that KPCs are evolving","DOI":"10.1128\/AAC.01165-15"},{"issue":"3","key":"617_CR83","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ofid\/ofx101","volume":"4","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature. Open Forum Infect Dis. 2017;4(3):22\u20135. https:\/\/doi.org\/10.1093\/ofid\/ofx101.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"617_CR84","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"\u2022 Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, et al. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59(8):4856\u201360. https:\/\/doi.org\/10.1128\/AAC.00843-15. This study illustrated the efficacy of the novel beta-lactamse inhibitor, RPX7009, against KPCs","journal-title":"Antimicrob Agents Chemother"},{"key":"617_CR85","unstructured":"\u2022 Kaye K, Vazquez J, Mathers, A, Daikos G, Alexander E, Loutit J, et al. Clinical outcomes of serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) in TANGO-II (a phase 3 study of the treatment of CRE infections). Poster Presentation at IDWeek San Diego, CA; 2017. This presentation provided the outcome data of patients treated with meropenem-vaborbactam for treatment of CRE infections."},{"issue":"2","key":"617_CR86","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01695-15","volume":"60","author":"N Kohira","year":"2016","unstructured":"Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60(2):729\u201334. https:\/\/doi.org\/10.1128\/AAC.01695-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"617_CR87","unstructured":"Achaogen. (2016). Achaogen announces positive results in phase 3 cUTI and CRE clinical trials of plazomicin. Retrieved from http:\/\/investors.achaogen. com\/releasedetail.cfm?ReleaseID=1003671."},{"issue":"8","key":"617_CR88","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1128\/AAC.00830-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"\u2022 Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman J, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029\u201331. https:\/\/doi.org\/10.1128\/AAC.00830-15. This study evaluated the activity of imipenem with relebactam against Klebsiella pneumoniae carbapenemases","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"617_CR89","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/jac\/dkt178","volume":"68","author":"DM Livermore","year":"2013","unstructured":"Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286\u201390. https:\/\/doi.org\/10.1093\/jac\/dkt178.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"617_CR90","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H, Zelentisky S, Golden A, Schweizer F, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567\u201388. https:\/\/doi.org\/10.1007\/s40265-016-0545-8.","journal-title":"Drugs"},{"issue":"11","key":"617_CR91","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548\u201358. https:\/\/doi.org\/10.1128\/AAC.01288-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"617_CR92","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"\u2022 Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59(3):1802\u20135. https:\/\/doi.org\/10.1128\/AAC.04809-14. This study illustrated the activity of eravacycline against Klebsiella pneumoniae carbapenemase-producing organisms","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"617_CR93","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"\u2022\u2022 Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with Eravacycline (IGNITE 1) trial. JAMA Surg. 2017;152(3):224. https:\/\/doi.org\/10.1001\/jamasurg.2016.4237. This study showed the effiicacy of eravacycline for treatment of complicated intra-abdominal infections","journal-title":"JAMA Surg"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11908-018-0617-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-018-0617-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-018-0617-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T22:57:09Z","timestamp":1744066629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11908-018-0617-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,5]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1007\/s11908-018-0617-x","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,5]]},"assertion":[{"value":"5 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ann Marie Porreca, Kaede V. Sullivan, and Jason C. Gallagher declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"13"}}